45 results about "Levocetirizine" patented technology

The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and / or modified-release elements, providing for drug delivery to the patient.

An exterior-applied levocetirizine hydrochloride for preventing and treating the anaphylaxia and inflammation without untoward effect is disclosed.

A resolution method of a levocetirizine chiral intermediates belongs to the technical field of fine organic chemical engineering. The method comprises the following specific steps: adding racemic 1-[(4-chlorophenyl)benzyl]piperazine and chiral ionic liquid in a reaction container to react at 10-100 DEG C for 1-10 hours, extracting with toluene for layering, adjusting the pH value of the aqueous phase with 10wt% of sodium hydroxide solution to 11-12, extracting with toluene again, and concentrating to crystallize after the post-treatment, thus obtaining the product. The chiral ionic liquid is used as the solvent and resolving agent, the technology is easy to operate, the efficiency is high, the yield of three wastes is low, the yield of the product is more than 34%, the melting range of the product is narrow, the melting point is 94-96 DEG C, the specific rotation [alpha] D is not more than -21.5 degrees (C1, toluene), the optical purity is not less than 99.0%, and the content is not less than 99.0%. The post-treatment is convenient, the ionic liquid can be used repeatedly and the resolution method is an economical, practical, green and environmentally friendly technology.

The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability.

The invention relates to the field of pharmaceutical preparations, in particular to a composition and a preparation method thereof, an oral liquid and a preparation method thereof. The preparation method of the composition is as follows: mixing montelukast sodium with the first water to obtain a montelukast sodium solution; mixing levocetirizine hydrochloride with the second water to adjust the pH value to 6.5-9 to obtain Levocetirizine hydrochloride solution; get montelukast sodium solution and levocetirizine hydrochloride solution to mix. The montelukast sodium in the oral liquid provided by the invention has high stability, does not contain organic solvents and surfactants, is convenient for children to take medicine, and has a simple preparation process.

The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof using diglycolic acid or derivatives thereof and new intermediates used in that process.

The present invention provides an antianaphylactic medicine solution preparation containing Levocetirizine. In 1000 ml of medicine composite solution 0.5-20g of zocetirizine or its pharmacal acceptable salt, 20-100 g of polyvinyl pyrrolidone, 5-50g of poloxamer and 10-250g of polyethylene glycol 400 are contained.

The present invention describes a novel process for the preparation of levocetirizine and pharmaceutically acceptable acid addition salts thereof using diglycolic acid or derivatives thereof and new intermediates used in that process.